apl. Prof. Dr. Lucie Heinzerling

Medizinische Fakultät Department of Dermatology

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) (2020) Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, et al. Journal article Four cases of erysipelas-like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors (2020) Pföhler C, Hassel JC, Heinzerling L, Müller CS Journal article Monitoring skin metastases during immuno- and targeted therapy using total-body 3D photography (2020) Erdmann M, Heinzerling L, Schuler G, Berking C, Schliep S Journal article Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease (2020) Weiß J, Kirchberger M, Heinzerling L Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Skin Cancer in Childhood and Adolescents: Treatment and Implications for the Long-Term Follow-Up (2020) Heinzerling L, Eigentler TK Authored book Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study (2019) Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, et al. Journal article A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution C-reactive protein as an early marker of immune-related adverse events (2019) Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L Journal article